These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38610138)

  • 1. Staff-Facilitated Telemedicine Care Delivery for Treatment of Hepatitis C Infection among People Who Inject Drugs.
    Kim RG; McDonell C; McKinney J; Catalli L; Price JC; Morris MD
    Healthcare (Basel); 2024 Mar; 12(7):. PubMed ID: 38610138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community-Based Point-of-Diagnosis Hepatitis C Treatment for Marginalized Populations: A Nonrandomized Controlled Trial.
    Morris MD; McDonell C; Luetkemeyer AF; Thawley R; McKinney J; Price JC
    JAMA Netw Open; 2023 Oct; 6(10):e2338792. PubMed ID: 37862013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial for a peer-facilitated telemedicine hepatitis c treatment intervention for people who use drugs in rural communities: study protocol for the "peer tele-HCV" study.
    Herink MC; Seaman A; Leichtling G; Larsen JE; Gailey T; Cook R; Thomas A; Korthuis PT
    Addict Sci Clin Pract; 2023 May; 18(1):35. PubMed ID: 37245041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
    Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
    Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engaging people who use drugs in clinical research: integrating facilitated telemedicine for HCV into substance use treatment.
    Talal AH; George SJ; Talal LA; Dharia A; Ventuneac A; Baciewicz G; Perumalswami PV; Dickerson SS
    Res Involv Engagem; 2023 Aug; 9(1):63. PubMed ID: 37533127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Facilitated telemedicine for hepatitis C virus: Addressing challenges for improving health and life for people with opioid use disorder.
    Talal AH; Jaanimägi U; Dharia A; Dickerson SS
    Health Expect; 2023 Dec; 26(6):2594-2607. PubMed ID: 37641398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peer-delivered intervention to reduce harm and improve the well-being of homeless people with problem substance use: the SHARPS feasibility mixed-methods study.
    Parkes T; Matheson C; Carver H; Foster R; Budd J; Liddell D; Wallace J; Pauly B; Fotopoulou M; Burley A; Anderson I; MacLennan G
    Health Technol Assess; 2022 Feb; 26(14):1-128. PubMed ID: 35212621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does a simplified algorithm and integrated HCV care model improve linkage to care, retention, and cure among people who inject drugs? A pragmatic quality improvement randomized controlled trial protocol.
    Klaman SL; Godino JG; Northrup A; Lewis SV; Tam A; Carrillo C; Lewis R; Matthews E; Mendez B; Reyes L; Rojas S; Ramers C
    BMC Infect Dis; 2024 Jan; 24(1):105. PubMed ID: 38238686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaling and Sustaining Facilitated Telemedicine to Expand Treatment Access Among Underserved Populations: A Qualitative Study.
    Ventuneac A; Dickerson SS; Dharia A; George SJ; Talal AH
    Telemed J E Health; 2023 Dec; 29(12):1862-1869. PubMed ID: 37252770
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C).
    Talal AH; Markatou M; Sofikitou EM; Brown LS; Perumalswami P; Dinani A; Tobin JN
    Contemp Clin Trials; 2022 Jan; 112():106632. PubMed ID: 34813962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs.
    Midgard H; Finbråten AK; Malme KB; Berg-Pedersen RM; Tanum L; Olsen IC; Bjørnestad R; Dalgard O
    Trials; 2020 Jun; 21(1):524. PubMed ID: 32539853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development, implementation, and feasibility of site-specific hepatitis C virus treatment workflows for treating vulnerable, high-risk populations: protocol of the Erase Hep C study - a prospective single-arm intervention trial.
    Desai A; O'Neal L; Reinis K; Chang P; Brown C; Stefanowicz M; Kuang A; Agrawal D; Bhavnani D; Mercer T
    Pilot Feasibility Stud; 2023 May; 9(1):78. PubMed ID: 37158965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidisciplinary teams, efficient communication, procedure services, and telehealth improve cirrhosis care: A qualitative study.
    Serper M; Agha A; Garren PA; Taddei TH; Kaplan DE; Groeneveld PW; Werner RM; Shea JA
    Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37219845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the use and challenges of implementing virtual visits during COVID-19 in primary care and lessons for sustained use.
    Mohammed HT; Hyseni L; Bui V; Gerritsen B; Fuller K; Sung J; Alarakhia M
    PLoS One; 2021; 16(6):e0253665. PubMed ID: 34166441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying barriers and facilitators along the hepatitis C care cascade to inform human-centered design of contextualized treatment protocols for vulnerable populations in Austin, Texas: a qualitative study.
    Desai A; O'Neal L; Reinis K; Brown C; Stefanowicz M; Kuang A; Agrawal D; Bhavnani D; Mercer T
    Implement Sci Commun; 2023 Aug; 4(1):98. PubMed ID: 37592306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare stakeholders' perceptions and experiences of factors affecting the implementation of critical care telemedicine (CCT): qualitative evidence synthesis.
    Xyrichis A; Iliopoulou K; Mackintosh NJ; Bench S; Terblanche M; Philippou J; Sandall J
    Cochrane Database Syst Rev; 2021 Feb; 2(2):CD012876. PubMed ID: 33599282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in blood pressure among users of lay health worker or volunteer operated community-based blood pressure programs over time: a systematic review protocol.
    Skar P; Young L; Gordon C
    JBI Database System Rev Implement Rep; 2015 Oct; 13(10):30-40. PubMed ID: 26571280
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.